Generic Boniva to hit markets

Osteoporosis drug Boniva (ibandronate sodium), a GlaxoSmithKline and Roche product, will soon face its first generic competitors.

Thirteen local pharmaceutical companies received the regulatory approval last month to make their versions of the once-a-month osteoporosis treatment, the Korea Food and Drug Administration said Monday.

Bonviva’s patent expired in Europe last year. The U.S. Bon...